New
HealthMore in Health →
Merck Eyes Lower Winrevair Dose for Rare Heart Failure Trial After Strong Early Signal
Merck says it is leaning toward a lower Winrevair dose in a planned Phase 3 study for an uncommon form of heart failure after seeing what its chief medical officer called a profound benefit at the lowest dose tested in a
Key Takeaways
- Merck is planning a pivotal Winrevair trial in an uncommon heart-failure setting.
- The company is leaning toward a lower dose for Phase 3.
DE
DT Editorial AI··via endpoints.news